Lars Ny
Overview
Explore the profile of Lars Ny including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DePalo D, Dugan M, Naqvi S, Ollila D, Hieken T, Block M, et al.
Cancer
. 2024 Nov;
131(1):e35636.
PMID: 39522025
Background: Isolated limb infusion and perfusion (ILI/ILP) has been a mainstay treatment for unresectable melanoma in-transit metastases (ITM), but increased use of immune checkpoint inhibitors (ICI) and intralesional therapy (talimogene...
2.
Karlsson J, Sah V, Olofsson Bagge R, Kuznetsova I, Iqba M, Alsen S, et al.
Elife
. 2024 Sep;
12.
PMID: 39312285
Uveal melanoma (UM) is a rare melanoma originating in the eye's uvea, with 50% of patients experiencing metastasis predominantly in the liver. In contrast to cutaneous melanoma, there is only...
3.
Holmberg C, Zijlker L, Katsarelias D, Huibers A, Wouters M, Schrage Y, et al.
Eur J Surg Oncol
. 2024 Sep;
50(12):108653.
PMID: 39266404
No abstract available.
4.
Holmberg C, Zijlker L, Katsarelias D, Huibers A, Wouters M, Schrage Y, et al.
Eur J Surg Oncol
. 2024 Mar;
50(6):108265.
PMID: 38493679
Objective: ILP has shown to achieve high response rates in patients with melanoma ITM. Possibly there is a synergistic mechanism of action of ILP and anti-PD1. The aim of this...
5.
Olofsson Bagge R, Nelson A, Shafazand A, All-Eriksson C, Cahlin C, Elander N, et al.
Ann Surg
. 2024 Feb;
PMID: 38420778
Objective: To investigate overall survival (OS) and health-related quality of life (HRQOL) of first-line isolated hepatic perfusion (IHP) compared to best alternative care (BAC) for patients with uveal melanoma liver...
6.
Bjursten S, Zhao Z, Al Remawi H, Studahl M, Pandita A, Simren J, et al.
EBioMedicine
. 2024 Jan;
100:104955.
PMID: 38171113
Background: Cancer treatment with immune checkpoint inhibition (ICI) can cause immune-related adverse events in the central nervous system (CNS irAE). There are no blood biomarkers to detect CNS irAE. We...
7.
Holmberg C, Mikiver R, Isaksson K, Ingvar C, Moncrieff M, Nielsen K, et al.
Ann Surg Oncol
. 2023 Aug;
30(13):8026-8033.
PMID: 37574516
Background: The key prognostic factors for staging patients with primary cutaneous melanoma are Breslow thickness, ulceration, and sentinel lymph node (SLN) status. The multicenter selective lymphadenectomy trial (MSLT-I) verified SLN...
8.
Sah V, Jespersen H, Karlsson J, Nilsson L, Bergqvist M, Johansson I, et al.
Cancer Res Commun
. 2023 Jun;
3(5):884-895.
PMID: 37377898
Purpose: Patients with metastatic uveal melanoma have limited therapeutic options and high mortality rate so new treatment options are needed. Patients And Methods: We previously reported that patients treated with...
9.
Inci K, Nilsson B, Ny L, Stromberg U, Wilking N, Lindskog S, et al.
Cancers (Basel)
. 2023 Jun;
15(11).
PMID: 37296984
(1) Background: Targeted therapy is used alone or together with chemotherapy in metastatic colorectal cancer. The aim of this study was to assess overall survival and medical costs in a...
10.
Helgadottir H, Ny L, Ullenhag G, Falkenius J, Mikiver R, Olofsson Bagge R, et al.
J Natl Cancer Inst
. 2023 May;
115(9):1077-1084.
PMID: 37227040
Background: Adjuvant treatments with PD-1 and BRAF+MEK inhibitors statistically significantly prolong recurrence-free survival in stage III cutaneous melanoma. Yet, the effect on overall survival is still unclear. Based on recurrence-free...